L17 #ACR23 @RheumNow Afimetoran TLR7/8 inhib for cutaneous lupus Safety: No SAEs, mild-mod AEs, lower than PBO Nasopharyngitis & bronchitis Trough concentration consistent from D8 to 113, support 30 mg qd CLASI change; MCDI 50% Afim v 0% PB, CLASI-50 Afim 50% v 0% Inhib of IFNGS https://t.co/cKYY6rmIWE

L17 @ #ACR23 New therapy on horizon for cutaneous LE (CLE)? ⭐️AFIMETORAN ➡️ TLR7/8 inhibitor ➡️1st-in-class orally bioavailable, potent ⭐️Phase Ib trial ➡️Criteria: 👉18-65 yo SLE vs biopsy proven CLE 👉CLE Dz Area & Severity Index (CLASI-A) at least 6 👉ANA… https://t.co/HPqw4d0AHl https://t.co/5u9aEvzdMb

Telitacicept (BlyS/APRIL inhibitor) ph3 in RA wholly in China, after SLE approval there (SLE trial now w global sites) Efficacy okay, no better than other b/tsDMARDs What's the hook here, in a crowded RA market incl biosimilars? Safety does look good though #ACR23 L20 @RheumNow https://t.co/UzQ0f18E2A

ICYMI Interesting study by Dr LWGarcia et al: 👉IFN-a serum levels predicted failure to respond to tx 2 years after a flare in pts w/ LN 👉Pts w/⬆️BL IFN-a levels had greater risk of having 2 or more subsequent flares #ACR23 ABST2297 @RheumNow @ZahiTouma https://t.co/WJZnNUPUbT

Q for Rheumatologists: How often do you counsel appropriate SLE patients about cervical ca screening and/or vaccination? Re: PAPILUP Study A#1479 #ACR23 - shows PAP findings of HR-HPV+abnml cytology comparable to HIV+ pts @RheumNow

Agimeteran a TLR7/8i 30 mg in #cutaneous #lupus which differentiated from placebo. Small single site #RCT. Far more pts improved #CLASI by 50% vs PBO #ACR23 #ACRbest ⁦@RheumNow⁩ ⁦@ACRheum⁩ L15 In larger RCT now! https://t.co/zssjgpydVY

Burden of flare & organ damage of SLE pts from the Asia Pacific cohort: Prevalence of organ damage at BL - 39% Incidence of damage accrual: ~58 per 1000PY Pts w/ >=2 flares accrued damage Flares independently⬆️risk of damage accrual #ACR23 ABST2261 @RheumNow @rheumarhyme https://t.co/nW34sI9FdP

#ACR23 Abstr#2332 We need to compliment the Complement #SLE. Post-hoc analysis of SOC + PBO from Dapirolizumab Phase 2 RCT showed reduced response in patients who flared with low complement levels vs normal or persistent activity. To consider as a stratifier @RheumNow https://t.co/BcN6ExLD0s

Treatment of lupus nephritis #ACR23 Dall’Era M, Furie R, Mosca M @RheumNow https://t.co/Md2DsOrY5F

Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY

Lupus Nephritis and the Target with PR3+ in proliferative classes with more aggresive phenotype.. #Lupus biopsy.. #ACR23 https://t.co/fGJX57hWx4

Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv

• Dr. John Cush

Latest in Lupus Treatment at #ACR23 • Dr. Dall’Era & Dr. Furie • Approach to Lupus Nephritis 🫘 • Treating Non-Renal SLE / Skin #Lupus #RheumTwitter #Rheumatology https://t.co/sagVipdNJe

#Lupus #ACR23🦋 🌍A wonderful session unraveling scientific breakthroughs of #CAR T cell therapy 🔥Promising step towards future in revolutionizing Lupus T/t💡📑 💡Keeps efficacy of other vaccines intact! Follow this thread showcasing other imp findings #ACRambassador 1/2 https://t.co/aNFTmJiH0X